ClinicalTrials.gg
CompletedNCT02310321Updated Sep 2, 2025Results posted

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

A Phase 1/2 interventional study of Gilteritinib and Idarubicin in Acute Myeloid Leukemia and FLT3-mutated Acute Myeloid Leukemia, sponsored by Astellas Pharma Inc. Completed at 55 sites in 3 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Astellas Pharma Inc · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
97
Allocation
Non-randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
16th of 31
97 · median 97
Started
2015
with 2 others
Phase 1/2
8 of 31
2 open now
Registered
4th of 31
by date
Lead sponsor
3 of 31
Astellas Pharma Inc

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 16th largest by enrollment, is one of 3 that started in 2015, is one of 8 in phase 1/2, and was the 4th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of phase 1 part in this study was to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting toxicity (DLT) in newly diagnosed Acute Myeloid Leukemia (AML) subjects. Phase 1 part also evaluated safety and tolerability and characterized the pharmacokinetic (PK) parameters of ASP2215 concomitant with induction and consolidation chemotherapy as well as evaluated the PK parameters of cytarabine concomitant with ASP2215.

The purpose of phase 2 part was to evaluate efficacy of ASP2215 in combination with induction therapy. Phase 2 cohort also evaluated safety and characterized the PK parameters of ASP2215 in combination with induction and consolidation therapy followed by maintenance therapy in newly diagnosed FLT3-mutated AML subjects.

Read the detailed description

This study was composed of Phase 1 part (the dose-evaluation part and the expansion part) and Phase 2 part.

In the dose-evaluation part of Phase 1 part, at least 3 subjects received ASP2215 at each dose (low, middle, and high) for determination of MTD and/or RED. Treatment of AML in Phase 1 part was composed of 3 periods of therapy: remission induction, consolidation, and maintenance. The decision of whether or not to proceed to the next dose was made based on the occurrence of DLT during Cycle 1 of the induction period.

In the expansion part of Phase 1 part, a maximum of 3 subjects received ASP2215 at RED that had been recommended in the dose-evaluation part and the safety was assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods.

In Phase 2 part, Subjects received ASP2215 at the recommended dose established in Phase 1 part. The target population was limited to newly diagnosed FLT3-mutated AML.

03

Conditions studied

  • Acute Myeloid Leukemia
  • FLT3-mutated Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • Cytarabine
  • Idarubicin
  • ASP2215
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

[Phase 1 part]

  • Subject is defined as having previously untreated de novo AML according to the World Health Organization (WHO) criteria (2008) within 28 days prior to study enrollment.
  • Subject has an (ECOG) performance status of ≤ 2.
  • Subject must meet all of the following criteria in the laboratory test at screening:

    • Serum (AST) and alanine aminotransferase (ALT) levels of ≤ 2.5 × institutional (ULN)
    • Total serum level of ≤ 1.5 × institutional ULN
    • Serum creatinine level of ≤ 1.5 × institutional ULN or an estimated (eGFR) of > 50 mL/min
  • Subject is suitable for oral administration of ASP2215.
  • Female subject falls under the following:

    • Of non-:
    • ・ (defined as at least 1 year with no menses without a medical reason such as drug administration) at screening, or
    • ・Documented surgically sterile or status post-hysterectomy (at least 1 month prior to screening)
    • Of childbearing potential:
    • ・Has a negative result for the pregnancy test at screening, and
    • ・Agrees to use an appropriate starting at screening and throughout the study period and for 60 days after the final study drug administration
  • Female subject agrees not to breastfeed starting at screening and throughout the study period and for 60 days after the final study drug administration.
  • Female subject agrees not to donate ova starting at screening and throughout the study period and for 60 days after the final study drug administration.
  • Male subject and his female spouse/partner who is of childbearing potential agrees to use an appropriate contraception starting at screening and throughout the study period and for 120 days after the final study drug administration.
  • Male subject agrees not to donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
  • Subject agrees not to participate in another interventional study while on study treatment.
  • Subject can be admitted during the induction period.

[Phase 2 part]

  • Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to World Health Organization (WHO) classification (2017) documented within 28 days prior to enrollment.
  • Subject is positive for FLT3-ITD and/or TKD mutation in bone marrow or whole blood as determined by the central lab. Registration by the local lab result is not acceptable.
  • Subject has an ECOG performance status (PS) 0 to 1. Subject who has an ECOG PS 2 is eligible only if the primary disease related symptoms such as pneumonia and febrile neutropenia are the cause of PS score.
  • Subject is suitable for oral administration of ASP2215.
  • Female subject is not pregnant and at least 1 of the following conditions apply:

    • Not a woman of childbearing potential (WOCBP)
    • WOCBP who agrees to follow the contraceptive guidance from the time of through at least 180 days after final study treatment administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration.
  • Male subject and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and continue throughout the study period and for 120 days after the final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
  • Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 120 days after the final study treatment administration.
  • Subject agrees not to participate in another interventional study while on treatment.
  • Subject must meet the following criteria as indicated on the clinical laboratory tests:

    • Serum creatinine ≤ 1.5 × institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 50 mL/min/1.73m\^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.
    • Serum total bilirubin ≤ 2.5 mg/dL (43 μmol/L), except for subjects with Gilbert's syndrome.
    • Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x ULN. If liver abnormality by the primary disease is suspected, subject may be pre-registered to initiate the chemotherapy. Prior to registration, AST/ALT values must meet the criteria to continue the study.
    • Serum magnesium ≥ institutional lower limit of normal (LLN). Subject may pre-register without magnesium value, but subject must meet the criteria prior to the full registration on Day 8.
    • Serum potassium ≥ institutional lower limit of normal (LLN).

Exclusion criteria

Exclusion Criteria:

[Phase 1 part]

  • Subject was diagnosed with acute promyelocytic leukemia (APL).
  • Subject has breakpoint cluster region-abelson (BCR-ABL)-positive leukemia (chronic myelogenous leukemia in blast crisis).
  • Subject has active malignant tumors other than AML or myelodysplastic syndrome (MDS).
  • Subject has received prior AML treatment except for the following:

    • Urgent leukapheresis
    • Hydroxyurea administration for emergency treatment of hyperleukocytosis (≤ 7 days)
    • Administration of retinoic acid before the diagnosis to exclude APL (≤ 7 days)
    • Supportive care using growth factors or cytokines
    • administration to treat or blood transfusion reactions
  • Subject has clinically active central nervous system leukemia.
  • Subject has disseminated intravascular coagulation (DIC).
  • Subject has had major surgery within 28 days prior to the first study drug administration.
  • Subject has had radiation therapy within 28 days prior to the first study drug administration.
  • Subject has congestive heart failure of (NYHA) class 3 or 4, or subject with a past history of congestive heart failure of NYHA class 3 or 4 and in whom echocardiogram (ECHO) or Multiple Gate Acquisition () scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of \< 45%.
  • Subject has cardiac impairment or a cardiac disease, including any one of the following:

    • Complete left bundle branch block
    • Obligate use of a cardiac pacemaker
    • Long syndrome at Screening
    • Prolongation of the QTc interval (> 450 ms) on (ECG) at screening
    • Right bundle branch block + left anterior hemiblock (bifascicular block)
    • Angina pectoris within 3 months prior to study drug administration
    • Acute myocardial infarction within 3 months prior to study drug administration
  • Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
  • Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Subject requires treatment with concomitant drugs that target serotonin 5HT1 or 5HT2B receptors or sigma receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
  • Subject has an active uncontrollable infection.
  • Subject is known to have (HIV) infection.
  • Subject has active or C or other active hepatic disorders.
  • Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.
  • Potassium and magnesium levels of below institutional lower limit of normal in the laboratory test at screening.

[Phase 2 part]

  • Subject was diagnosed with acute promyelocytic leukemia (APL).
  • Subject has known BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
  • Subject has therapy-related AML.
  • Subject has active malignant tumors other than AML.
  • Subject has received previous therapy for AML, with the exception of the following:

    • Emergency leukapheresis
    • Emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 10 days
    • Preemptive treatment with retinoic acid prior to exclusion of APL ≤ 7 days
    • Growth factor or cytokine support
    • Steroids for the treatment of hypersensitivity or transfusion reactions.
  • Subject has QTcF interval > 450 ms (average of triplicate determinations based on central reading).
  • Subject with long QT syndrome.
  • Subject has clinically active central nervous system leukemia.
  • Subject has had major surgery within 4 weeks prior to the first study dose.
  • Subject has radiation therapy within 4 weeks prior to the first study dose.
  • Subject has immediate life-threatening, severe complications of leukemia such as severe uncontrolled bleeding and/or severe disseminated intravascular coagulation
  • Subject is known to have human immunodeficiency virus infection.
  • Subject has active hepatitis B or C.
  • Subject has an uncontrolled infection. An infection controlled with an approved or closely monitored antibiotic/antiviral/antifungal treatment is allowed.
  • Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure of NYHA class 3 or 4 and echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of \< 45%.
  • Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
  • Subject requires treatment with concomitant drugs that target serotonin 5HT2B receptors or sigma nonspecific receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
  • Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Subject has prior , except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \< 5 years previously will not be allowed.
  • Subject has any condition which makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Phase 1: Dose Evaluation (DEv)

    Induction period: Participants received 120 milligrams (mg) gilteritinib (3 tablets of 40 mg) orally, once daily from day 4 to 17 combined with chemotherapy (idarubicin: 12 mg per square meters per day \[mg/m\^2/day\] on days 1 to 3, cytarabine: 100 mg/m\^2/day on days 1 to 7) via intravenous (IV) infusion; in cycles (C) 1 and 2 (1 cycle= 42 days). Consolidation period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from day 1 to 14 combined with chemotherapy (cytarabine: 1500 mg/m\^2, twice daily on days 1, 3, and 5) via IV infusion; in the consolidation period in C1 to 3 (1 cycle= 28 days). Duration of infusion was determined by site clinical practice and local package insert in both induction and consolidation periods.. Maintenance period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from days 1 to 28 in the maintenance period in C1 to 26 or untill discontinuation criterion is met (1 cycle= 28 days).

    Drug: Gilteritinib · Drug: Idarubicin · Drug: Cytarabine

  • Experimental
    Phase 1: Dose Expansion (DEx)

    Induction period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once a day from days 4 to 17 in combination with chemotherapy (idarubicin: 12 mg/m\^2/day on days 1 to 3, cytarabine: 100 mg/m\^2/day on days 1 to 7) via IV infusion; in the induction period in C1 and 2 (1 cycle= 42 days). Consolidation period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once a day from days 1 to 14 in combination with chemotherapy (cytarabine: 1500 mg/m\^2, twice daily on days 1, 3, and 5) via IV infusion; in the consolidation period in C1 to 3 (1 cycle= 28 days). Duration of infusion was determined based on site clinical practice and the local package insert in both induction and consolidation periods. Maintenance period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once a day from days 1 to 28 in the maintenance period in C1 to 26 or a discontinuation criterion is met (1 cycle= 28 days).

    Drug: Gilteritinib · Drug: Idarubicin · Drug: Cytarabine

  • Experimental
    Phase 2: FLT3-mutated AML

    Induction period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from days 8 until blood recovery combined with chemotherapy (idarubicin: 12 mg/m\^2/day on days 1 to 3, cytarabine: 100 mg/m\^2/day on days 1 to 7) via IV infusion; in C1 and 2. Each cycle was extended until blood recovery was observed. Consolidation period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from days 1 until blood recovery combined with chemotherapy (cytarabine: 1500 mg/m\^2, twice daily on days 1, 3, and 5) via IV infusion; in C1 to 3. Each cycle was extended until blood recovery was observed. Duration of infusion was based on site clinical practice and the local package insert in both induction and consolidation periods. Maintenance period: Participants received 120 mg gilteritinib (3 tablets of 40 mg) orally, once daily from days 1 to 28 in the maintenance period in C1 to 26 or a discontinuation criterion is met (1 cycle= 28 days).

    Drug: Gilteritinib · Drug: Idarubicin · Drug: Cytarabine

Interventions

  • Once-daily oral administration on 14 consecutive days in every cycle in each period.

    Also known as: Xospata, ASP2215

  • Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.

  • Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days. Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5.

06

What researchers measure

Primary outcomes

  1. Phase 1 Part: Maximum Tolerated Dose (MTD) of Gilteritinib

    The MTD was defined as the highest dose of gilteritinib at which the posterior mean of the DLT incidence during Cycle 1 of induction therapy was estimated to be closest to 33%.

    Time frame: Day 1 up to the end of Induction period cycle 1 (up to 42 days)

  2. Phase 1 Part: Recommended Expansion Dose (RED) of Gilteritinib

    RED was the recommended dose used in Phase 2 of the study that was decided by the sponsor's responsible person by comprehensively assessing the data obtained from the study.

    Time frame: Day 1 up to the end of Induction period cycle 1 (up to 42 days)

  3. Phase 1 Part: Number of Participants With Dose Limiting Toxicities (DLTs) of Gilteritinib

    DLTs were defined as: Any Grade ≥ 3 non-hematologic or extramedullary toxicity with the following exceptions: * Anorexia or fatigue * Grade 3 nausea and/or vomiting if participant did not require tube feeding or total parenteral nutrition, or diarrhea if the events did not require or prolong hospitalization that could be managed to grade ≤ 2 with standard antiemetic or antidiarrheal medications used at prescribed dose within 7 days of onset. * Grade 3 mucositis that resolved to Grade ≤ 2 within 7 days of onset, fever with neutropenia, with or without infection, infection * Grade 4 peripheral neutrophil count \< 500/cubic millimeters (mm\^3) * Platelet count \< 20,000/mm\^3 due to bone marrow hypoplasia * Grade ≥ 3 platelet count \< 50,000/mm\^3 accompanying bleeding * Grade 4 platelet count \< 25,000/mm\^3 requiring platelet transfusion DLT was assessed until cycle 1 of dose evaluation induction period and until cycle 1 of dose expansion consolidation period.

    Time frame: Day 1 up to the end of Consolidation Cycle 1 (approximately up to 4 months)

  4. Phase 1 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE included both serious and non-serious AEs. TEAE for Phase 1 was defined as an AE observed after the date of first dose until 30 days after the last dose.

    Time frame: From the date of first dose up to 30 days after the last dose ( maximum duration up to approximately 4.1 years)

  5. Phase 2 Part: Complete Remission (CR) Rate: Induction Period

    Percentage of participants with CR was reported. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm3 and platelet count of ≥ 100,000/mm3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%.

    Time frame: From the date of first dose up to the start of Consolidation (approximately up to 4 months)

Secondary outcomes

  1. Phase 1 Part: Maximum Concentration (Cmax) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

    Cmax was derived from the PK samples collected. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

    Time frame: Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1

  2. Phase 1 Part: Time to Attain Cmax (Tmax) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

    Tmax was derived from the PK samples collected.

    Time frame: Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1

  3. Phase 1 Part: Area Under Plasma Concentration-time Curve From Time 0 to 24 (AUC24) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

    AUC24 was derived from the PK samples collected. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

    Time frame: Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1

  4. Phase 1 Part: Area Under The Concentration-Time Curve From The Time Zero to The Last Measurable Concentration (AUClast) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

    AUClast was derived from the PK samples collected. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

    Time frame: Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1

  5. Phase 1 Part: Plasma Trough Concentration (Ctrough) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

    Ctrough is the plasma concentration prior to drug administration. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

    Time frame: Induction period: Pre-dose on Cycle 1 Day 8, 11, and 17 Consolidation period: Pre-dose on Cycle 1 Day 6 and 15

  6. Phase 1 Part: Plasma Trough Concentration of Cytarabine Concomitant With Gilteritinib With Induction and Consolidation Period

    Ctrough is the plasma concentration prior to drug administration. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

    Time frame: Induction period: Predose on Cycle 1 Day 1, 3, and 8 Consolidation period: Predose on Cycle 1 Day 2 and 6

  7. Phase 2 Part: Plasma Trough Concentration of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

    Ctrough is the plasma concentration prior to drug administration.

    Time frame: Induction period : Predose on Cycle 1 Day 15 and 21 Consolidation period: Predose on Cycle 1 Day 8 and 15

  8. Phase 2 Part: Overall Survival (OS)

    Overall survival (OS) was defined as the time from the date of first dose of day 1 to the date of death due to any cause. Participants still alive or lost to follow up was censored at the time they were last known to be alive. Kaplan-Meier (KM) estimate was used for analysis.

    Time frame: From the date of first dose up to the date of death (maximum duration: approximately 4.4 years)

  9. Phase 2 Part: Event Free Survival (EFS)

    Event-free survival (EFS): time from date of first dose of study regimen until date of documented relapse, treatment failure or death from any cause, whichever occurred first. KM estimate was used for analysis. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in bone marrow aspirate (BMA)/reappearance of significant numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%. Treatment failure: participants who failed to achieve composite complete remission (CRc) or who discontinued treatment due to "lack of efficacy" without previous response. CRc: rate of all complete \& incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recover (CRi). CRp: met all CR criteria at post-baseline visit, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria at post-baseline visit, except unrecovered neutrophil count (\< 1,000/mm\^3). CR: defined in outcome measure #5.

    Time frame: From the date of first dose up to the date of documented relapse, treatment failure or death from any cause (maximum duration: approximately 4.4 years)

  10. Phase 2 Part: Relapse Free Survival (RFS)

    Relapse-free survival (RFS): time from date of achievement of first CRc until relapse or death from any cause. KM estimate was used for analysis. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in bone marrow aspirate (BMA)/reappearance of significant numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%. CRc: rate of all complete \& incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recover (CRi). CRp: met all CR criteria at post-baseline visit, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria at post-baseline visit, except unrecovered neutrophil count (\< 1,000/mm\^3). CR: morphologically leukemia-free state at post-baseline visit, having neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods \& extramedullary leukemia. Blast counts in peripheral blood was ≤ 2%.

    Time frame: From the date of achievement of first CRc up to the date of documented relapse or death from any cause (maximum duration: approximately 3.9 years)

  11. Phase 2 Part: CR Rate After Consolidation and Maintenance Period

    Percentage of participants with CR was reported. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. Derived response assessment after the consolidation period refers to the best response from the start of treatment in the induction period until the end of the consolidation period and for the maintenance period refers to the best response from the start of treatment in the induction period until the end of the maintenance period.

    Time frame: CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)

  12. Phase 2 Part: CR Rate Without Minimal Residual Disease (MRD) After Each Treatment Therapy Period

    CR% without MRD reported. CR rate without MRD after each treatment therapy was defined similarly as CR rate after each treatment therapy. Responders achieve that the best response is CR and MRD status was negative. CR was defined as a morphologically leukemia-free state, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. Derived response assessment after the IP refers to the best response from the start of treatment in the IP until the end of the IP, after CP refers to the best response from the start of treatment in the IP until the end of the CP and for the MP refers to the best response from the start of treatment in the IP until the end of the MP.

    Time frame: IP: From date of first dose up to end of period (approximately 1.4 years), CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)

  13. Phase 2 Part: CR With Partial Hematological Recovery (CRh) Rate After Each Treatment Therapy Period

    Percentage of participants with CRh was reported. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery neutrophil count≥ 500/mm\^3 and platelet count ≥ 50,000/mm\^3, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%. Derived response assessment after the IP refers to the best response from the start of treatment in the IP until the end of the IP, after CP refers to the best response from the start of treatment in the IP until the end of the CP and for the MP refers to the best response from the start of treatment in the IP until the end of the MP.

    Time frame: IP: From date of first dose up to end of period (approximately 1.4 years), CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)

  14. Phase 2 Part: Composite CR (CRc) Rate After Each Treatment Therapy Period

    Percentage of participants with CRc reported. CRc: rate of all complete \& incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recovery (CRi). CRp: met all CR criteria, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria, except unrecovered neutrophil count (\< 1,000/mm\^3). CR: morphologically leukemia-free state, having neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods \& extramedullary leukemia. Blast counts in peripheral blood was ≤ 2%. Derived response assessment after the IP refers to the best response from the start of treatment in the IP until the end of the IP, after CP refers to the best response from the start of treatment in the IP until the end of the CP and for the MP refers to the best response from the start of treatment in the IP until the end of the MP.

    Time frame: IP: From date of first dose up to end of period (approximately 1.4 years), CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)

  15. Phase 2 Part: CR/CRh Rate After Each Treatment Therapy Period

    Percentage of participants with CR/CRh was reported. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery neutrophil count≥ 500/mm\^3 and platelet count ≥ 50,000/mm\^3, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%. Derived response assessment after the IP refers to the best response from the start of treatment in the IP until the end of the IP, after CP refers to the best response from the start of treatment in the IP until the end of the CP and for the MP refers to the best response from the start of treatment in the IP until the end of the MP.

    Time frame: IP: From date of first dose up to end of period (approximately 1.4 years), CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)

  16. Phase 2 Part: Duration of CR

    Duration of CR was defined as the time from the date of achieving first CR until the date of first documented relapse for participants who achieved CR. KM estimate was used for analysis. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%.

    Time frame: From the date of achieving CR up to the date of documented relapse (maximum duration: approximately 2.6 years)

  17. Phase 2 Part: Duration of CR/CRh

    Duration of CR/CRh is defined as the time from the date of achieving first CR/CRh until the date of first documented relapse for participants who achieved CR/CRh. KM estimate was used for analysis. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery neutrophil count≥ 500/mm\^3 and platelet count ≥ 50,000/mm\^3, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%.

    Time frame: From the date of achieving CR/CRh up to the date of documented relapse (maximum duration: approximately 2.6 years)

  18. Phase 2 Part: Duration of CRh

    Duration of CRh was defined as the time from date of achieving first CRh until date of first documented relapse for participants who achieved CRh. KM estimate was used for analysis. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery neutrophil count≥ 500/mm\^3 and platelet count ≥ 50,000/mm\^3, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%.

    Time frame: From the date of achieving CRh up to the date of documented relapse (maximum duration: approximately 2.6 years)

  19. Phase 2 Part: Duration of CRc

    Duration of CRc is defined as the time from the date of achieving first CRc until the date of first documented relapse for participants who achieved CRc. KM estimate was used for analysis. CRc: rate of all complete \& incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recover (CRi). CRp: met all CR criteria at post-baseline visit, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria at post-baseline visit, except unrecovered neutrophil count (\< 1,000/mm\^3). CR: morphologically leukemia-free state at post-baseline visit, having neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods \& extramedullary leukemia. Blast counts in peripheral blood was ≤ 2%. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%.

    Time frame: From the date of achieving CRc up to the date of documented relapse (maximum duration: approximately 2.7 years)

  20. Phase 2 Part: Duration of Response (DoR)

    DoR: from first day of achieving CRc (CR+ CRp,+CRi)/partial remission (PR) to first day of relapse. KM estimate was used for analysis. CR: morphologically leukemia-free state at post-baseline visit, having neutrophil count of ≥ 1,000/mm\^3 \& platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods \& extramedullary leukemia. Peripheral blood blast counts was ≤ 2%. CRp: met all CR criteria at post-baseline visit, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria at post-baseline visit, except unrecovered neutrophil count (\< 1,000/mm\^3). PR: condition with regeneration of normal hematopoietic cells in bone marrow, no detectable blasts, ≥ 50% decrease of blasts in BMA \& total bone marrow blasts of 5-25%. No evidence of extramedullary leukemia. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%

    Time frame: From the date of achieving CR, CRp, CRi/PR up to the date of documented relapse (maximum duration: approximately 2.7 years)

  21. Phase 2 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE for Phase 2 was defined as an AE observed after the date of first dose until 30 days after the last dose. TEAE included both serious and non-serious AEs.

    Time frame: From the date of first dose up to 30 days after the last dose ( maximum duration up to approximately 4.4 years)

07

Results

Posted Oct 16, 2024

Participant flow

Participants with newly diagnosed acute myeloid leukemia (AML) and participants newly diagnosed FMS-like tyrosine kinase-3, FMS-related tyrosine kinase 3 (FLT3)-mutated AML; were enrolled in Phase 1 and Phase 2, respectively.

Phase 1(DEv):IP (2 Cycles;42 Days/Cycle)
Participant flow — Phase 1(DEv):IP (2 Cycles;42 Days/Cycle)
MilestonePhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Started300
Completed200
Not completed100
Withdrew: Miscellaneous100
Phase 1(DEv):CP (3 Cycles;28 Days/Cycle)
Participant flow — Phase 1(DEv):CP (3 Cycles;28 Days/Cycle)
MilestonePhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Started200
Completed100
Not completed100
Withdrew: Miscellaneous100
Phase 1(DEv):MP(26 Cycles;28 Days/Cycle)
Participant flow — Phase 1(DEv):MP(26 Cycles;28 Days/Cycle)
MilestonePhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Started100
Completed000
Not completed100
Withdrew: Miscellaneous100
Phase 1(DEx):IP (2 Cycles;42 Days/Cycle)
Participant flow — Phase 1(DEx):IP (2 Cycles;42 Days/Cycle)
MilestonePhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Started0100
Completed030
Not completed070
Withdrew: Adverse event010
Withdrew: Miscellaneous040
Withdrew: There is no cr, crp, or cri after 2 cycles of therapy010
Withdrew: Disease relapse010
Phase 1(DEx):CP (3 Cycles;28 Days/Cycle)
Participant flow — Phase 1(DEx):CP (3 Cycles;28 Days/Cycle)
MilestonePhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Started030
Completed030
Not completed000
Phase 1(DEx):MP(26 Cycles;28 Days/Cycle)
Participant flow — Phase 1(DEx):MP(26 Cycles;28 Days/Cycle)
MilestonePhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Started030
Completed000
Not completed030
Withdrew: Micellaneous030
Phase 2:IP(2 Cycles;up to 56 Days/Cycle)
Participant flow — Phase 2:IP(2 Cycles;up to 56 Days/Cycle)
MilestonePhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Started0084
Completed0062
Not completed0022
Withdrew: Miscellaneous002
Withdrew: Disease relapse002
Withdrew: Physician decision006
Withdrew: Withdrawal by subject004
Withdrew: Lack of efficacy003
Withdrew: Death003
Withdrew: Adverse event002
Phase 2:CP(4 Cycles;up to 28 Days/Cycle)
Participant flow — Phase 2:CP(4 Cycles;up to 28 Days/Cycle)
MilestonePhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Started0057
Completed0042
Not completed0015
Withdrew: Miscellaneous007
Withdrew: Disease relapse004
Withdrew: Physician decision004
Phase 2:MP(26 Cycles; 28 Days/Cycle)
Participant flow — Phase 2:MP(26 Cycles; 28 Days/Cycle)
MilestonePhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Started0046
Completed0023
Not completed0023
Withdrew: Disease relapse0011
Withdrew: Miscellaneous002
Withdrew: Adverse event003
Withdrew: Death001
Withdrew: Physician decision006

Outcome measures

PrimaryPhase 1 Part: Maximum Tolerated Dose (MTD) of Gilteritinib

The MTD was defined as the highest dose of gilteritinib at which the posterior mean of the DLT incidence during Cycle 1 of induction therapy was estimated to be closest to 33%.

Time frame:
Day 1 up to the end of Induction period cycle 1 (up to 42 days)
Reported as:
Number · miligram (mg)
Phase 1 Part: Maximum Tolerated Dose (MTD) of Gilteritinib
miligram (mg)Phase 1: Dose Evaluation (DEv)
Phase 1 Part: Maximum Tolerated Dose (MTD) of GilteritinibNA
PrimaryPhase 1 Part: Recommended Expansion Dose (RED) of Gilteritinib

RED was the recommended dose used in Phase 2 of the study that was decided by the sponsor's responsible person by comprehensively assessing the data obtained from the study.

Time frame:
Day 1 up to the end of Induction period cycle 1 (up to 42 days)
Reported as:
Number · mg
Phase 1 Part: Recommended Expansion Dose (RED) of Gilteritinib
mgPhase 1: Dose Evaluation (DEv)
Phase 1 Part: Recommended Expansion Dose (RED) of Gilteritinib120
PrimaryPhase 1 Part: Number of Participants With Dose Limiting Toxicities (DLTs) of Gilteritinib

DLTs were defined as: Any Grade ≥ 3 non-hematologic or extramedullary toxicity with the following exceptions: * Anorexia or fatigue * Grade 3 nausea and/or vomiting if participant did not require tube feeding or total parenteral nutrition, or diarrhea if the events did not require or prolong hospitalization that could be managed to grade ≤ 2 with standard antiemetic or antidiarrheal medications used at prescribed dose within 7 days of onset. * Grade 3 mucositis that resolved to Grade ≤ 2 within 7 days of onset, fever with neutropenia, with or without infection, infection * Grade 4 peripheral neutrophil count \< 500/cubic millimeters (mm\^3) * Platelet count \< 20,000/mm\^3 due to bone marrow hypoplasia * Grade ≥ 3 platelet count \< 50,000/mm\^3 accompanying bleeding * Grade 4 platelet count \< 25,000/mm\^3 requiring platelet transfusion DLT was assessed until cycle 1 of dose evaluation induction period and until cycle 1 of dose expansion consolidation period.

Time frame:
Day 1 up to the end of Consolidation Cycle 1 (approximately up to 4 months)
Reported as:
Number · Participants
Phase 1 Part: Number of Participants With Dose Limiting Toxicities (DLTs) of Gilteritinib
ParticipantsPhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)
Phase 1 Part: Number of Participants With Dose Limiting Toxicities (DLTs) of Gilteritinib01
PrimaryPhase 1 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE included both serious and non-serious AEs. TEAE for Phase 1 was defined as an AE observed after the date of first dose until 30 days after the last dose.

Time frame:
From the date of first dose up to 30 days after the last dose ( maximum duration up to approximately 4.1 years)
Reported as:
Number · Participants
Phase 1 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)
Phase 1 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)310
PrimaryPhase 2 Part: Complete Remission (CR) Rate: Induction Period

Percentage of participants with CR was reported. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm3 and platelet count of ≥ 100,000/mm3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%.

Time frame:
From the date of first dose up to the start of Consolidation (approximately up to 4 months)
Reported as:
Number · Percentage of participants
Phase 2 Part: Complete Remission (CR) Rate: Induction Period
Percentage of participantsPhase 2: FLT3-mutated AML
Phase 2 Part: Complete Remission (CR) Rate: Induction Period50 (40.4 to 59.6)
SecondaryPhase 1 Part: Maximum Concentration (Cmax) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

Cmax was derived from the PK samples collected. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

Time frame:
Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1
Reported as:
Mean · nanograms per milliliter (ng/mL)
Phase 1 Part: Maximum Concentration (Cmax) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
nanograms per milliliter (ng/mL)Phase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)
Induction Period246 ± 154132 ± 27.5
Consolidation period133 ± NA73.5 ± 17.5
SecondaryPhase 1 Part: Time to Attain Cmax (Tmax) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

Tmax was derived from the PK samples collected.

Time frame:
Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1
Reported as:
Median · hours
Phase 1 Part: Time to Attain Cmax (Tmax) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
hoursPhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)
Induction period3.93 (3.82 to 6.13)5.77 (3.83 to 9.77)
Consolidation period2.94 (1.85 to 4.03)4.32 (3.90 to 9.70)
SecondaryPhase 1 Part: Area Under Plasma Concentration-time Curve From Time 0 to 24 (AUC24) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

AUC24 was derived from the PK samples collected. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

Time frame:
Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1
Reported as:
Mean · ng*hr/mL
Phase 1 Part: Area Under Plasma Concentration-time Curve From Time 0 to 24 (AUC24) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
ng*hr/mLPhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)
Induction period3880 ± 25302210 ± 567
Consolidation period2110 ± NA1160 ± 204
SecondaryPhase 1 Part: Area Under The Concentration-Time Curve From The Time Zero to The Last Measurable Concentration (AUClast) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

AUClast was derived from the PK samples collected. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

Time frame:
Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1
Reported as:
Mean · ng*hr/mL
Phase 1 Part: Area Under The Concentration-Time Curve From The Time Zero to The Last Measurable Concentration (AUClast) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
ng*hr/mLPhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)
Induction period3830 ± 25202190 ± 552
Consolidation period2090 ± NA1150 ± 202
SecondaryPhase 1 Part: Plasma Trough Concentration (Ctrough) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

Ctrough is the plasma concentration prior to drug administration. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

Time frame:
Induction period: Pre-dose on Cycle 1 Day 8, 11, and 17 Consolidation period: Pre-dose on Cycle 1 Day 6 and 15
Reported as:
Mean · ng/mL
Phase 1 Part: Plasma Trough Concentration (Ctrough) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
ng/mLPhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)
Induction period: Cycle 1 day 8245 ± 144245 ± 77.7
Induction period: Cycle 1 day 11283 ± 183417 ± 203
Induction period: Cycle 1 day 17393 ± 252455 ± 143
Consolidation period: Cycle 1 day 6194 ± NA159 ± 12.1
Consolidation period: Cycle 1 day 15285 ± NA171 ± 154
SecondaryPhase 1 Part: Plasma Trough Concentration of Cytarabine Concomitant With Gilteritinib With Induction and Consolidation Period

Ctrough is the plasma concentration prior to drug administration. It was planned that standard deviation(SD) would only be calculated if there are more than 3 participants analyzed otherwise, SD was not calculated.

Time frame:
Induction period: Predose on Cycle 1 Day 1, 3, and 8 Consolidation period: Predose on Cycle 1 Day 2 and 6
Reported as:
Mean · ng/mL
Phase 1 Part: Plasma Trough Concentration of Cytarabine Concomitant With Gilteritinib With Induction and Consolidation Period
ng/mLPhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)
Induction period: Cycle 1 Day 10 ± NA0 ± NA
Induction period: Cycle 1 Day 334.9 ± 14.5210 ± 417
Induction period: Cycle 1 Day 858.8 ± 8.67110 ± 107
Consolidation period: Cycle 1 Day 24.87 ± NA9.39 ± 2.19
Consolidation period: Cycle 1 Day 67.09 ± NA11.8 ± 1.91
SecondaryPhase 2 Part: Plasma Trough Concentration of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy

Ctrough is the plasma concentration prior to drug administration.

Time frame:
Induction period : Predose on Cycle 1 Day 15 and 21 Consolidation period: Predose on Cycle 1 Day 8 and 15
Reported as:
Mean · ng/mL
Phase 2 Part: Plasma Trough Concentration of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
ng/mLPhase 2: FLT3-mutated AML
Induction Period: Cycle 1 Day 15522 ± 331
Induction Period: Cycle 1 Day 21647 ± 518
Consolidation Period: Cycle 1 Day 8244 ± 152
Consolidation Period: Cycle 1 Day 15375 ± 249
SecondaryPhase 2 Part: Overall Survival (OS)

Overall survival (OS) was defined as the time from the date of first dose of day 1 to the date of death due to any cause. Participants still alive or lost to follow up was censored at the time they were last known to be alive. Kaplan-Meier (KM) estimate was used for analysis.

Time frame:
From the date of first dose up to the date of death (maximum duration: approximately 4.4 years)
Reported as:
Median · Months
Phase 2 Part: Overall Survival (OS)
MonthsPhase 2: FLT3-mutated AML
Phase 2 Part: Overall Survival (OS)48.2 (45.1 to NA)
SecondaryPhase 2 Part: Event Free Survival (EFS)

Event-free survival (EFS): time from date of first dose of study regimen until date of documented relapse, treatment failure or death from any cause, whichever occurred first. KM estimate was used for analysis. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in bone marrow aspirate (BMA)/reappearance of significant numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%. Treatment failure: participants who failed to achieve composite complete remission (CRc) or who discontinued treatment due to "lack of efficacy" without previous response. CRc: rate of all complete \& incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recover (CRi). CRp: met all CR criteria at post-baseline visit, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria at post-baseline visit, except unrecovered neutrophil count (\< 1,000/mm\^3). CR: defined in outcome measure #5.

Time frame:
From the date of first dose up to the date of documented relapse, treatment failure or death from any cause (maximum duration: approximately 4.4 years)
Reported as:
Median · Months
Phase 2 Part: Event Free Survival (EFS)
MonthsPhase 2: FLT3-mutated AML
Phase 2 Part: Event Free Survival (EFS)25.0 (11.3 to 48.2)
SecondaryPhase 2 Part: Relapse Free Survival (RFS)

Relapse-free survival (RFS): time from date of achievement of first CRc until relapse or death from any cause. KM estimate was used for analysis. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in bone marrow aspirate (BMA)/reappearance of significant numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%. CRc: rate of all complete \& incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recover (CRi). CRp: met all CR criteria at post-baseline visit, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria at post-baseline visit, except unrecovered neutrophil count (\< 1,000/mm\^3). CR: morphologically leukemia-free state at post-baseline visit, having neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods \& extramedullary leukemia. Blast counts in peripheral blood was ≤ 2%.

Time frame:
From the date of achievement of first CRc up to the date of documented relapse or death from any cause (maximum duration: approximately 3.9 years)
Reported as:
Median · Months
Phase 2 Part: Relapse Free Survival (RFS)
MonthsPhase 2: FLT3-mutated AML
Phase 2 Part: Relapse Free Survival (RFS)27.8 (17.4 to 39.8)
SecondaryPhase 2 Part: CR Rate After Consolidation and Maintenance Period

Percentage of participants with CR was reported. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. Derived response assessment after the consolidation period refers to the best response from the start of treatment in the induction period until the end of the consolidation period and for the maintenance period refers to the best response from the start of treatment in the induction period until the end of the maintenance period.

Time frame:
CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)
Reported as:
Number · Percentage of participants
Phase 2 Part: CR Rate After Consolidation and Maintenance Period
Percentage of participantsPhase 2: FLT3-mutated AML
After consolidation period63.4 (52.0 to 73.8)
After maintenance period63.4 (52.0 to 73.8)
SecondaryPhase 2 Part: CR Rate Without Minimal Residual Disease (MRD) After Each Treatment Therapy Period

CR% without MRD reported. CR rate without MRD after each treatment therapy was defined similarly as CR rate after each treatment therapy. Responders achieve that the best response is CR and MRD status was negative. CR was defined as a morphologically leukemia-free state, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. Derived response assessment after the IP refers to the best response from the start of treatment in the IP until the end of the IP, after CP refers to the best response from the start of treatment in the IP until the end of the CP and for the MP refers to the best response from the start of treatment in the IP until the end of the MP.

Time frame:
IP: From date of first dose up to end of period (approximately 1.4 years), CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)
Reported as:
Number · Percentage of participants
Phase 2 Part: CR Rate Without Minimal Residual Disease (MRD) After Each Treatment Therapy Period
Percentage of participantsPhase 2: FLT3-mutated AML
After Induction Period18.3 (10.6 to 28.4)
After Consolidation Period35.4 (25.1 to 46.7)
After Maintenance Period35.4 (25.1 to 46.7)
SecondaryPhase 2 Part: CR With Partial Hematological Recovery (CRh) Rate After Each Treatment Therapy Period

Percentage of participants with CRh was reported. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery neutrophil count≥ 500/mm\^3 and platelet count ≥ 50,000/mm\^3, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%. Derived response assessment after the IP refers to the best response from the start of treatment in the IP until the end of the IP, after CP refers to the best response from the start of treatment in the IP until the end of the CP and for the MP refers to the best response from the start of treatment in the IP until the end of the MP.

Time frame:
IP: From date of first dose up to end of period (approximately 1.4 years), CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)
Reported as:
Number · Percentage of participants
Phase 2 Part: CR With Partial Hematological Recovery (CRh) Rate After Each Treatment Therapy Period
Percentage of participantsPhase 2: FLT3-mutated AML
After Induction Period17.1 (9.7 to 27.0)
After Consolidation Period9.8 (4.3 to 18.3)
After Maintenance Period9.8 (4.3 to 18.3)
SecondaryPhase 2 Part: Composite CR (CRc) Rate After Each Treatment Therapy Period

Percentage of participants with CRc reported. CRc: rate of all complete \& incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recovery (CRi). CRp: met all CR criteria, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria, except unrecovered neutrophil count (\< 1,000/mm\^3). CR: morphologically leukemia-free state, having neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods \& extramedullary leukemia. Blast counts in peripheral blood was ≤ 2%. Derived response assessment after the IP refers to the best response from the start of treatment in the IP until the end of the IP, after CP refers to the best response from the start of treatment in the IP until the end of the CP and for the MP refers to the best response from the start of treatment in the IP until the end of the MP.

Time frame:
IP: From date of first dose up to end of period (approximately 1.4 years), CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)
Reported as:
Number · Percentage of participants
Phase 2 Part: Composite CR (CRc) Rate After Each Treatment Therapy Period
Percentage of participantsPhase 2: FLT3-mutated AML
After Induction Period86.6 (77.3 to 93.1)
After Consolidation Period87.8 (78.7 to 94.0)
After Maintenance Period87.8 (78.7 to 94.0)
SecondaryPhase 2 Part: CR/CRh Rate After Each Treatment Therapy Period

Percentage of participants with CR/CRh was reported. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery neutrophil count≥ 500/mm\^3 and platelet count ≥ 50,000/mm\^3, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%. Derived response assessment after the IP refers to the best response from the start of treatment in the IP until the end of the IP, after CP refers to the best response from the start of treatment in the IP until the end of the CP and for the MP refers to the best response from the start of treatment in the IP until the end of the MP.

Time frame:
IP: From date of first dose up to end of period (approximately 1.4 years), CP: From date of first dose up to end of period (approximately 1.8 years), MP: From date of first dose up to the end of period (approximately 3.8 years)
Reported as:
Number · Percentage of participants
Phase 2 Part: CR/CRh Rate After Each Treatment Therapy Period
Percentage of participantsPhase 2: FLT3-mutated AML
After Induction Period67.1 (55.8 to 77.1)
After Consolidation Period73.2 (62.2 to 82.4)
After Maintenance Period73.2 (62.2 to 82.4)
SecondaryPhase 2 Part: Duration of CR

Duration of CR was defined as the time from the date of achieving first CR until the date of first documented relapse for participants who achieved CR. KM estimate was used for analysis. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%.

Time frame:
From the date of achieving CR up to the date of documented relapse (maximum duration: approximately 2.6 years)
Reported as:
Median · Months
Phase 2 Part: Duration of CR
MonthsPhase 2: FLT3-mutated AML
Phase 2 Part: Duration of CRNA (NA to NA)
SecondaryPhase 2 Part: Duration of CR/CRh

Duration of CR/CRh is defined as the time from the date of achieving first CR/CRh until the date of first documented relapse for participants who achieved CR/CRh. KM estimate was used for analysis. CR was defined as a morphologically leukemia-free state at the post-baseline visit, having a neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods and no evidence of extramedullary leukemia. The blast counts in peripheral blood was ≤ 2%. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery neutrophil count≥ 500/mm\^3 and platelet count ≥ 50,000/mm\^3, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%.

Time frame:
From the date of achieving CR/CRh up to the date of documented relapse (maximum duration: approximately 2.6 years)
Reported as:
Median · Months
Phase 2 Part: Duration of CR/CRh
MonthsPhase 2: FLT3-mutated AML
Phase 2 Part: Duration of CR/CRhNA (NA to NA)
SecondaryPhase 2 Part: Duration of CRh

Duration of CRh was defined as the time from date of achieving first CRh until date of first documented relapse for participants who achieved CRh. KM estimate was used for analysis. CRh was defined as a condition at the post baseline visit, having bone marrow blasts \< 5%, partial hematologic recovery neutrophil count≥ 500/mm\^3 and platelet count ≥ 50,000/mm\^3, no evidence of extramedullary leukemia and could be classified as CR. The blast counts in peripheral blood was ≤ 2%. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%.

Time frame:
From the date of achieving CRh up to the date of documented relapse (maximum duration: approximately 2.6 years)
Reported as:
Median · Months
Phase 2 Part: Duration of CRh
MonthsPhase 2: FLT3-mutated AML
Phase 2 Part: Duration of CRhNA (NA to NA)
SecondaryPhase 2 Part: Duration of CRc

Duration of CRc is defined as the time from the date of achieving first CRc until the date of first documented relapse for participants who achieved CRc. KM estimate was used for analysis. CRc: rate of all complete \& incomplete remissions i.e. CR + CR with incomplete platelet recovery (CRp) + CR with incomplete hematological recover (CRi). CRp: met all CR criteria at post-baseline visit, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria at post-baseline visit, except unrecovered neutrophil count (\< 1,000/mm\^3). CR: morphologically leukemia-free state at post-baseline visit, having neutrophil count of ≥ 1,000/mm\^3 and platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods \& extramedullary leukemia. Blast counts in peripheral blood was ≤ 2%. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%.

Time frame:
From the date of achieving CRc up to the date of documented relapse (maximum duration: approximately 2.7 years)
Reported as:
Median · Months
Phase 2 Part: Duration of CRc
MonthsPhase 2: FLT3-mutated AML
Phase 2 Part: Duration of CRcNA (NA to NA)
SecondaryPhase 2 Part: Duration of Response (DoR)

DoR: from first day of achieving CRc (CR+ CRp,+CRi)/partial remission (PR) to first day of relapse. KM estimate was used for analysis. CR: morphologically leukemia-free state at post-baseline visit, having neutrophil count of ≥ 1,000/mm\^3 \& platelet count of ≥ 100,000/mm\^3, bone marrow blasts \< 5%. No evidence of Auer rods \& extramedullary leukemia. Peripheral blood blast counts was ≤ 2%. CRp: met all CR criteria at post-baseline visit, except unrecovered platelet count (\< 100,000/mm\^3). CRi: met all CR criteria at post-baseline visit, except unrecovered neutrophil count (\< 1,000/mm\^3). PR: condition with regeneration of normal hematopoietic cells in bone marrow, no detectable blasts, ≥ 50% decrease of blasts in BMA \& total bone marrow blasts of 5-25%. No evidence of extramedullary leukemia. Relapse: reappearance of leukemic blasts in peripheral blood (\>2%)/≥ 5% blasts in BMA/reappearance of numbers of peripheral blasts and an increase in percentage of blasts in BMA to \> 25%

Time frame:
From the date of achieving CR, CRp, CRi/PR up to the date of documented relapse (maximum duration: approximately 2.7 years)
Reported as:
Median · Months
Phase 2 Part: Duration of Response (DoR)
MonthsPhase 2: FLT3-mutated AML
Phase 2 Part: Duration of Response (DoR)NA (NA to NA)
SecondaryPhase 2 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE for Phase 2 was defined as an AE observed after the date of first dose until 30 days after the last dose. TEAE included both serious and non-serious AEs.

Time frame:
From the date of first dose up to 30 days after the last dose ( maximum duration up to approximately 4.4 years)
Reported as:
Number · Participants
Phase 2 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPhase 2: FLT3-mutated AML
Phase 2 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)84

Adverse events

Collected over Adverse events: Phase 1: From the date of first dose up to 30 days after the last dose ( maximum duration up to approximately 4.1 years) Phase 2: From the date of first dose up to 30 days after the last dose ( maximum duration up to approximately 4.4 years) All-cause mortality: From randomization up to approximately 9.4 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Dose Evaluation (DEv)0/3 (0%)2/3 (66.7%)3/3 (100%)
Phase 1: Dose Expansion (DEx)0/10 (0%)1/10 (10%)10/10 (100%)
Phase 2: FLT3-mutated AML25/84 (29.8%)45/84 (53.6%)84/84 (100%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventPhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
Hepatic function abnormalHepatobiliary disorders1/30/106/84
Liver function test abnormalInvestigations1/31/100/84
PneumoniaInfections and infestations0/30/109/84
SepsisInfections and infestations0/30/109/84
Febrile neutropeniaBlood and lymphatic system disorders0/30/105/84
PyrexiaGeneral disorders0/30/104/84
Cardiac failureCardiac disorders0/30/103/84
Septic shockInfections and infestations0/30/103/84
Drug-induced liver injuryHepatobiliary disorders0/30/102/84
Alanine aminotransferase increasedInvestigations0/30/102/84
Most frequent other events
Showing 10 of 110
Most frequent other events
EventPhase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AML
AnaemiaBlood and lymphatic system disorders3/36/1022/84
Febrile neutropeniaBlood and lymphatic system disorders3/39/1053/84
ThrombocytopeniaBlood and lymphatic system disorders3/32/1013/84
AlopeciaSkin and subcutaneous tissue disorders2/39/1015/84
White blood cell count decreasedInvestigations1/37/1015/84
LeukopeniaBlood and lymphatic system disorders2/32/107/84
NeutropeniaBlood and lymphatic system disorders2/33/1010/84
NauseaGastrointestinal disorders2/31/1027/84
OedemaGeneral disorders2/30/105/84
PneumoniaInfections and infestations2/35/1014/84

Baseline characteristics

Safety Analysis Set (SAF): All participants who received at least 1 dose of study drug were included.

Age, Continuous
Age, Continuous(Years)Phase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AMLTotal
Mean48.3 ± 1449.9 ± 1551 ± 14.450.8 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AMLTotal
Female234348
Male174149
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AMLTotal
Hispanic or Latino0000
Not Hispanic or Latino3108497
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Dose Evaluation (DEv)Phase 1: Dose Expansion (DEx)Phase 2: FLT3-mutated AMLTotal
American Indian or Alaska Native0000
Asian3108497
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

55 sites
  • Site JP81037
    Anjo, Aichi-ken, Japan
  • Site JP00003
    Nagoya, Aichi-ken, Japan
  • Site JP81003
    Nagoya, Aichi-ken, Japan
  • Site JP81027
    Nagoya, Aichi-ken, Japan
  • Site JP81038
    Toyohashi, Aichi-ken, Japan
  • Site JP81010
    Narita, Chiba, Japan
  • Site JP81039
    Matsuyama, Ehime, Japan
  • Site JP81007
    Yoshida-gun, Fukui, Japan
  • Site JP00002
    Maebashi, Gunma, Japan
  • Site JP81001
    Maebashi, Gunma, Japan
  • Site JP81026
    Fukuyama, Hiroshima, Japan
  • Site JP81018
    Ōtake, Hiroshima, Japan
  • Site JP81014
    Sapporo, Hokkaido, Japan
  • Site JP81015
    Sapporo, Hokkaido, Japan
  • Site JP81043
    Himeji, Hyōgo, Japan
  • Site JP00007
    Kobe, Hyōgo, Japan
  • Site JP81006
    Kobe, Hyōgo, Japan
  • Site JP81036
    Mito, Ibaraki, Japan
  • Site JP81023
    Tsukuba, Ibaraki, Japan
  • Site JP81020
    Kanazawa, Ishikawa-ken, Japan
  • Site JP81013
    Isehara, Kanagawa, Japan
  • Site JP00006
    Yokohama, Kanagawa, Japan
  • Site JP81005
    Yokohama, Kanagawa, Japan
  • Site JP81024
    Yokohama, Kanagawa, Japan
  • Site JP81035
    Sendai, Miyagi, Japan
  • SIte JP81011
    Ōmura, Nagasaki, Japan
  • Site JP81041
    Tenri, Nara, Japan
  • Site JP81022
    Shimono, Tochigi, Japan
  • Site JP81040
    Bunkyo-ku, Tokyo, Japan
  • Site JP00005
    Shinagawa-ku, Tokyo, Japan
  • Site JP81032
    Shinagawa-ku, Tokyo, Japan
  • Site JP81029
    Akita, Japan
  • Site JP81008
    Chiba, Japan
  • Site JP00001
    Fukuoka, Japan
  • Site JP81004
    Fukuoka, Japan
  • Site JP81025
    Fukuoka, Japan
  • Site JP81031
    Fukushima, Japan
  • Site JP81030
    Gifu, Japan
  • Site JP81033
    Kochi, Japan
  • Site JP81028
    Kumamoto, Japan
  • Site JP81016
    Kyoto, Japan
  • Site JP81012
    Nagasaki, Japan
  • Site JP81009
    Okayama, Japan
  • Site JP81019
    Osaka, Japan
  • Site JP81021
    Osaka, Japan
  • Site KR82005
    Busan, South Korea
  • Site KR82002
    Incheon, South Korea
  • Site KR82001
    Seoul, South Korea
  • Site KR82003
    Seoul, South Korea
  • Site KR82004
    Seoul, South Korea
  • Site KR82006
    Seoul, South Korea
  • Site TW88604
    Kaohsiung City, Taiwan
  • Site TW88602
    Taichung, Taiwan
  • Site TW88601
    Tainan, Taiwan
  • Site TW88603
    Taoyuan, Taiwan
09

References and documents

Publications

  • Sawa M, Miyamoto T, Kim HJ, Hiramatsu Y, Cheong JW, Ikezoe T, Naoe T, Akashi K, Morita S, Kosako M, Shimura M, Terada W, Kadokura T, Hill J, Miyawaki S, Gill SC, Heinloth A, Hasabou N. A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis. Ther Adv Hematol. 2026 Mar 11;17:20406207261419953. doi: 10.1177/20406207261419953. eCollection 2026. PubMed 41835842 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Aug 2021, 77 months.

Results were first posted in Oct 2024, 3 years 1 month after primary completion. A results delay was requested in Aug 2022.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 77 months is close to that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2014
First posted
Dec 8, 2014
StartActual
Feb 26, 2015
Primary completionActual
Aug 25, 2021
CompletionActual
Jul 9, 2024
Results delay requested
Aug 24, 2022
Results first posted
Oct 16, 2024
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02310321
Responsible party
Sponsor
First posted
Dec 8, 2014
Start date
Feb 26, 2015
Primary completion
Aug 25, 2021
Completion
Jul 9, 2024
Results posted
Oct 16, 2024
Last update
Sep 2, 2025

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion